AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02453490
Drug: Raltitrexed-based chemotherapy
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed: 2.0mg,iv,15min,d1,Oxaliplatin:85mg/m2 iv,d1, q2w
Trial: NCT02609139
Drug: PF-06650833
RxNorm normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 400mg modified release tablets administered under fasted conditions
Trial: NCT02609139
Drug: PF-06650833
RxNorm normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg modified release tablet administered under fasted conditions
Trial: NCT02609139
Drug: PF-06650833
RxNorm normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg modified release tablet administered under fasted conditions
Trial: NCT01970046
Drug: SP2086 50 mg q.d./Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks~* Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks
Trial: NCT02453490
Drug: Raltitrexed-based chemotherapy
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w
Trial: NCT01357655
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
Trial: NCT01357655
Drug: BMS-833923
RxNorm normalized name: BMS-833923
DrugBank: BMS-833923 (DB16844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
Trial: NCT02609139
Drug: PF-06650833
RxNorm normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 400mg modified release tablets administered with high fat meal food intake
Trial: NCT02609139
Drug: PF-06650833
RxNorm normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg modified released tablet administered with high fat meal food intake
Trial: NCT02609139
Drug: PF-06650833
RxNorm normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg modified release tablet administered with high fat meal food intake
Trial: NCT00068575
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m\^2 IV over 60 minutes on days 1, 8, 15, 29, 36, 43 - weekly for total 6 doses, during 5 1/2 weeks radiation therapy.
Trial: NCT00050154
Drug: ZARNESTRA, tipifarnib, R115777
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04289675
Drug: Interferon-Beta
RxNorm normalized name: Interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theses drugs have been administered as part of routine care. Biological samples that will be analyzed (blood and cerebrospinal fluid) have been taken as part of routine care.
Trial: NCT00868010
Drug: donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
Trial: NCT00806247
Drug: tapentadol HCl
RxNorm normalized name: tapentadol HCl
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00453362
Drug: erlotinib HCl
RxNorm normalized name: erlotinib HCl
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets taken orally 150 mg/day.
Trial: NCT03367754
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (immunoglobulin \[Ig\] G4 kappa isotype) that binds to PD-1, thus blocking the receptor from binding with its ligands. Single dose of Pembrolizumab 200 mg given via intravenous (IV) infusion.
Trial: NCT04127578
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 IV pulses administered as concomitant medication over 3 months
Trial: NCT04127578
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
Trial: NCT01691508
Drug: Mepolizumab
RxNorm normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.
Trial: NCT01656148
Drug: Fampridine-SR
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
Trial: NCT03392792
Drug: tissue plasminogen activator
RxNorm normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: role of tissue plasminogen activator in patient with acute ischemic stroke having selective criteria for rTPA
Trial: NCT04201990
Drug: Camrelizumab and Apatinib
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab, iv, Q3W; Apatinib, po, QD
Trial: NCT04453436
Drug: Tenofovir Disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Genotipic resistance test
Trial: NCT03480568
Drug: Alirocumab 150 MG/ML [Praluent]
RxNorm normalized name: alirocumab 150 MG/ML [Praluent]
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cholesterol-lowering therapy
Trial: NCT00470054
Drug: dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01038804
Drug: YM155
RxNorm normalized name: Sepantronium bromide
DrugBank: Sepantronium (DB17062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT01038804
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT03885427
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: evaluate sedative, and analgesic effects of oral or nebulized ketamine
Trial: NCT00193089
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel
Trial: NCT00193089
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine
Trial: NCT00193089
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab
Trial: NCT00134264
Drug: torcetrapib/atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00134264
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01878526
Drug: Alginic acid
RxNorm normalized name: Alginic Acid
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algycon 1 tab chew tid after meal
Trial: NCT01878526
Drug: placebo (for domperidone)
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (for domperidone) 1 tab oral tid before meal
Trial: NCT01878526
Drug: Domperidone
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: domperidone (10 mg) 1 tab oral tid before meal
Trial: NCT01878526
Drug: placebo (of alginic acid)
RxNorm normalized name: Alginic Acid
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (for alginic acid) 1 tab chew tid after meal
Trial: NCT01569659
Drug: Lurasidone
RxNorm normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 80 mg/day for up to 30 weeks
Trial: NCT01569659
Drug: Lurasidone
RxNorm normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Up to 240 mg/day for up to 30 weeks
Trial: NCT00049803
Drug: sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00887120
Drug: Lopinavir/ritonavir standard dose According to WHO simplified dosing table
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * BW 6-7.9 kg: 1.5 mL oral q 12 hr~* BW 8.0-16.9 kg: 2.0 ml oral q 12 hr~* BW 17.0-19.9 kg: 2.5 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 4.0 ml oral q 12 hr~* BW \> 35 kg: 5.0 ml oral q 12 hr~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)
Trial: NCT00887120
Drug: Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * BW 6-7.9 kg: 1.0 mL oral q 12 hr~* BW 8.0-16.9 kg: 1.5 ml oral q 12 hr~* BW 17.0-19.9 kg: 1.8 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 3.0 ml oral q 12 hr~* BW \> 35 kg: 3.5 ml oral q 12 h~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)
Trial: NCT03345823
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral; Tablet
Trial: NCT03345823
Drug: Placebo for Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral; Tablet
Trial: NCT00130195
Drug: imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00130195
Drug: daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00130195
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00153803
Drug: Erlotinib (tarceva)
RxNorm normalized name: erlotinib Oral Tablet [Tarceva]
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
Trial: NCT04177290
Drug: Sintilimab (M1b)
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT04177290
Drug: Sintilimab (approved)
RxNorm normalized name: glucose
DrugBank: Sintilimab (DB15765)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT04250064
Drug: Bevacizumab Injection
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Additional concurrent low-dose Bevacizumab with standard EBRT
Trial: NCT00862979
Drug: Everolimus (EVR)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)
Trial: NCT00862979
Drug: cyclosporine A (CyA)
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only
Trial: NCT00862979
Drug: tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only
Trial: NCT00130195
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00130195
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04526236
Drug: Methadone Injectable Product
RxNorm normalized name: methadone Injectable Product
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative use of placebo for pain management and remifentanil during the surgery.
Trial: NCT00862979
Drug: mycophenolate mofetil (MMF)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg or 500 mg tablets with a dose of 1500-3000 mg per day
Trial: NCT03100903
Drug: BI 655130
RxNorm normalized name: Immunoglobulin G1, anti-(human interleukin 36 receptor) (humanized monoclonal BI 655130 gamma1-chain), disulfide with humanized monoclonal BI 655130 kappa-chain, dimer
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT00283699
Drug: albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active drug or placebo dosed bid p o for 8days
Trial: NCT02821247
Drug: Aflibercept (Eylea, BAY86-5321)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection; should comply with the recommendations written in the local Summary of Product Characteristics (SPC) of the product
Trial: NCT00517647
Drug: ATMX
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication phase: After screening assessments are completed, the child will enter the medication phase of the study. The child will be started on atomoxetine at 0.5 mg/kg/day, with the dosage increased to a maximum dose of 1.8 mg/kg/day. The dose will be determined by how well the child responds to and tolerates the drug. The dose will be given twice a day to minimize side effects. After the optimum dose is determined, the child will be kept at this stable dose for 4 weeks.
Trial: NCT00433147
Drug: Afegostat tartrate
RxNorm normalized name: tartrate
DrugBank: Afegostat (DB04545)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01882647
Drug: 000-0551 Lotion
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01882647
Drug: Vehicle Lotion
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00218530
Drug: Lofexidine
RxNorm normalized name: LOFEXIDINE
DrugBank: Lofexidine (DB04948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01533298
Drug: SmofKabiven peripheral
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenously over 3 days infusion
Trial: NCT02757248
Drug: Volasertib
RxNorm normalized name: Volasertib
DrugBank: Volasertib (DB12062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib 75-150mg/m2 given intravenously on days 1 and 8
Trial: NCT00507949
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sachets of 160 mg of granulated. Dosage 160 mg /b.i.d. Duration 8 weeks.
Trial: NCT00867321
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01143727
Drug: Santyl
RxNorm normalized name: Santyl
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply one 24-hr period sufficient to cover the wound.
Trial: NCT00474110
Drug: Ketamine & hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See Detailed Description
Trial: NCT03588988
Drug: Dexmedetomidine IV infusion
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The DEX group injects DEX at 0.2 ug / kg / hr from 9 pm to 7 am. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
Trial: NCT02757248
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15
Trial: NCT02589496
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg every 3 weeks
Trial: NCT04641455
Drug: Water
RxNorm normalized name: Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of water before upper endoscopy
Trial: NCT03109379
Drug: Trospium-Releasing Intravesical System (TAR-302-5018)
RxNorm normalized name: trospium Extended Release Oral Capsule
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
Trial: NCT02108860
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
Trial: NCT02047539
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg/day of aspirin 1000 mg/day of sugar pill
Trial: NCT00587470
Drug: Candesartan
RxNorm normalized name: Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum vasodilation.
Trial: NCT00587470
Drug: atacand
RxNorm normalized name: Atacand
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: maximum vasodilation
Trial: NCT01387737
Drug: TA-7284-Low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TA-7284-Low
Trial: NCT01387737
Drug: TA-7284-High
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-7284-High
Trial: NCT00138515
Drug: vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT00397241
Drug: Drug: dorzolamide/timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01167725
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01167725
Drug: mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intraperitoneally
Trial: NCT01167725
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00397241
Drug: Drug: latanoprost/timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00397241
Drug: dorzolamide/timolol and latanoprost
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03120273
Drug: Dexlansoprazole Injection
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg q12h,30mg q12h,15mg qd,30mg qd for 5 days
Trial: NCT03120273
Drug: Lansoprazole Injection
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg q12h for 5 days.
Trial: NCT03292653
Drug: Sotagliflozin
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Trial: NCT00911898
Drug: MM-111
RxNorm normalized name: MM-111
DrugBank: MM-111 (DB17983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV
Trial: NCT00003528
Drug: raltitrexed
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV